Starch-poly-є-caprolactone Microparticles Reduce the Needed Amount of BMP-2
- 26 June 2009
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 467 (12) , 3138-3148
Abstract
BMP-2 is currently administered clinically using collagen matrices often requiring large amounts of BMP-2 due to burst release over a short period of time. We developed and tested a novel injectable drug delivery system consisting of starch-poly-є-caprolactone microparticles for inducing osteogenesis and requiring smaller amounts of BMP-2. We evaluated BMP-2 encapsulation efficiency and the in vitro release profile by enzyme-linked immunosorbent assay. BMP-2 was rapidly released during the first 12 hours, followed by sustained release for up to 10 days. We then evaluated the osteogenic potential of dexamethasone (standard osteogenic induction agent) and BMP-2 after incorporation and during release using an osteo/myoblast cell line (C2C12). Alkaline phosphatase activity was increased by released BMP-2. Mineralization occurred after stimulation with BMP-2-loaded microparticles. A luciferase assay for osteocalcin promoter activity showed high levels of activity upon treatment with BMP-2-loaded microparticles. In contrast, no osteogenesis occurred in C2C12 cells using dexamethasone-loaded microparticles. However, human adipose stem cells exposed to the microparticles produced high amounts of alkaline phosphatase. The data suggest starch-poly-є-caprolactone microparticles are suitable carriers for the incorporation and controlled release of glucocorticoids and growth factors. Specifically, they reduce the amount of BMP-2 needed and allow more sustained osteogenic effects.Keywords
This publication has 52 references indexed in Scilit:
- Preparation and characterization of starch-poly-ε-caprolactone microparticles incorporating bioactive agents for drug delivery and tissue engineering applicationsActa Biomaterialia, 2009
- Biodegradable gelatin microparticles as delivery systems for the controlled release of bone morphogenetic protein-2Acta Biomaterialia, 2008
- In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein‐2 in the early and late stages of osteoblast differentiationDevelopment, Growth & Differentiation, 2008
- Bone morphogenetic proteins in tissue engineering: the road from laboratory to clinic, part II (BMP delivery)Journal of Tissue Engineering and Regenerative Medicine, 2008
- BMP-2 vs. BMP-4 expression and activity in glucocorticoid-arrested MC3T3-E1 osteoblasts: Smad signaling, not alkaline phosphatase activity, predicts rescue of mineralizationGrowth Factors, 2008
- In vitro and in vivo osteoblastic differentiation of BMP‐2‐ and Runx2‐engineered skeletal myoblastsJournal of Cellular Biochemistry, 2006
- Quantification of growth factors in allogenic bone grafts extracted with three different methodsCell and Tissue Banking, 2006
- Bone Morphogenetic ProteinsGrowth Factors, 2004
- Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro.Journal of Cell Biology, 1991
- The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2Biochemical and Biophysical Research Communications, 1990